PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium

StreetInsider03-22

Autism (“ASD”) is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a greater than 780% increase in the number of autism cases ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2421586076?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-22 03:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2421586076","market":"us","top_or_hot":-1,"title":"PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium","media":"StreetInsider","content":"<div>\n<p>Autism (“ASD”) is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a greater than 780% increase in the number of autism cases\n...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=22963376\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-22 03:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=22963376><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Autism (“ASD”) is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a greater than 780% increase in the number of autism cases\n...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=22963376\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065732104.USD","symbol_name":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=22963376","article_id":"2421586076","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2421586076","pubTimestamp":1711048800,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"Autism  is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a greater than 780% increase in the number of autism cases. PaxMedica is focused on the development of novel anti-purinergic therapies  for the treatment of ASD and other serious conditions with intractable neurologic symptoms. The ASD therapeutics market was valued at $2.01 billion in 2023 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9%. PaxMedica , a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies  for the treatment of ASD and other serious conditions with intractable neurologic symptoms, is on a promising path to address the unmet medical needs of ASD, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","QID":"纳指两倍做空ETF",".IXIC":"NASDAQ Composite","BK4588":"碎股","PAX":"Patria Investments Ltd","PSQ":"纳指反向ETF","NDAQ":"纳斯达克OMX交易所","QQQ":"纳指100ETF","QLD":"纳指两倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4135":"资产管理与托管银行","SPB":"Spectrum Brands Holdings","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","TQQQ":"纳指三倍做多ETF","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","PXMD":"PaxMedica, Inc.","BK4018":"居家用品","BK4585":"ETF&股票定投概念","SQQQ":"纳指三倍做空ETF","BK4007":"制药"},"translate_title":"PaxMedica Inc。（纳斯达克：PXMD）开发管道，通过苏拉明钠解决自闭症谱系障碍患者未满足的需求","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPB":1,"PXMD":1,"NDAQ":1,".IXIC":1,"PAX":0.69,"TQQQ":0.6,"SQQQ":0.6,"QQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Autism (“ASD”) is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a greater than 780% increase in the number of autism cases\nPaxMedica is focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms\nThe ASD therapeutics market was valued at $2.01 billion in 2023 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9%\nThere is currently no approved pharmacologic treatment targeting the cause and symptoms. Current treatments only address the condition’s symptoms rather than targeting the pathophysiology itself\n\nResearchers used to believe that autism spectrum disorder only affected one in 2,500 children – today, that estimation is closer to one in 36 children. Between 1998 and 2018, research has found more than a 780% increase in the number of autism cases in the United Kingdom. This significant increase is partially due to the deeper understanding and awareness of autism and the number of physicians who can diagnose the condition (https://ibn.fm/o5oTZ).\nAutism spectrum disorder (“ASD”) is a developmental disorder affecting how individuals interact with other people, behavior, communication, and learning. This disorder can be diagnosed at any age, but symptoms often appear in the first two years of life. There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current treatments only address the condition’s symptoms rather than targeting the pathophysiology itself.\nPaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms, is on a promising path to address the unmet medical needs of ASD, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.\nPaxMedica is developing a robust lineup of products aimed at addressing ASD and associated neurodevelopmental conditions. Their flagship product under development holds promise in mitigating or even easing some of the most challenging factors of ASD, potentially facilitating smoother integration of autistic individuals into social settings and enhancing their quality of life.\nAt the forefront of PaxMedica’s initiatives are PAX-101 and PAX-102, leveraging the company’s exclusive source of suramin sodium, a broad-acting anti-purinergic therapy with a century-long history. Their ongoing endeavors encompass:\n\nPAX-101 (IV Suramin) for ASD – Having concluded a Phase 2B study in 2021 involving 52 subjects across six sites in South Africa, PAX-101 exhibits promising results in ASD management. Suramin’s efficacy, demonstrated in a dose range study, underscores its potential as a therapeutic agent for ASD, with findings presented to AACAP in October 2021.\nPAX-102 (Intranasal Suramin) – PaxMedica’s innovative intranasal suramin formulation is presently undergoing evaluation for its efficacy in ASD and other neurodevelopmental conditions.\nPAX-101 for HAT – Capitalizing on suramin’s historical usage in treating Human African Trypanosomiasis (“HAT”), PaxMedica is advancing PAX-101 as a therapeutic solution for this ailment, particularly focusing on early-stage East African HAT cases.\nSelective Anti-Purinergic Therapies – PaxMedica’s exploration extends to other APTs through preclinical studies targeting specific purinergic receptors. These investigations aim to uncover therapies that offer tailored benefits beyond suramin’s broad spectrum of action.\n\nThe ASD therapeutics market was valued at $2.01 billion in 2023 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9% (https://ibn.fm/lvMzA). There are many factors expected to influence this growth, including the growing prevalence of the disease globally, the rising awareness about ASD and the available options for treatment, and growing interest by investors making investments in R&D initiatives for effective drugs to treat ASD.\nFor more information, visit the company’s website at www.PaxMedica.com.\nNOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD\nAbout BioMedWire\nBioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.\nBMW is where breaking news, insightful content and actionable information converge.\nTo receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)\nFor more information, please visit https://www.BioMedWire.com\nPlease see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer\nBioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 Office[email protected]\nBioMedWire is powered by IBN","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2421586076"}